期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 40, 期 6, 页码 598-+出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.21.01845
关键词
-
类别
A proportion of lung cancer patients can benefit from immune checkpoint inhibitors (ICIs), but most patients experience disease progression during or after treatment. Immune resistance has different definitions based on clinical and biological features. Combination therapies are being developed to delay or prevent resistance to ICIs.
A proportion of patients with lung cancer experience long-term clinical benefit with immune checkpoint inhibitors (ICIs). However, most patients develop disease progression during treatment or after treatment discontinuation. Definitions of immune resistance are heterogeneous according to different clinical and biologic features. Primary resistance and acquired resistance, related to tumor-intrinsic and tumor-extrinsic mechanisms, are identified according to previous response patterns and timing of occurrence. The clinical resistance patterns determine differential clinical approaches. To date, several combination therapies are under development to delay or prevent the occurrence of resistance to ICIs, including the blockade of immune coinhibitory signals, the activation of those with costimulatory functions, the modulation of the tumor microenvironment, and the targeting T-cell priming. Tailoring the specific treatments with distinctive biologic resistance mechanisms would be ideal to improve the design and results of clinical trial. In this review, we reviewed the available evidence on immune resistance mechanisms, clinical definitions, and management of resistance to ICIs in lung cancer. We also reviewed data on novel strategies under investigation in this setting. (c) 2022 by American Society of Clinical Oncology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据